US Patent

US10688094 — Bromocriptine formulations

Method of Use · Assigned to Veroscience LLC · Expires 2032-04-30 · 6y remaining

Vulnerability score 68/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects pharmaceutical formulations of bromocriptine mesylate for improving glycemic control in the treatment of type 2 diabetes.

USPTO Abstract

The present application describes pharmaceutical formulations of bromocriptine mesylate and methods of manufacturing and using such formulations. The formulations are useful for improving glycemic control in the treatment of type 2 diabetes.

Drugs covered by this patent

bromocriptine-mesylate (BROMOCRIPTINE MESYLATE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2871`	—	bromocriptine-mesylate

Patent Metadata

Patent number: US10688094
Jurisdiction: US
Classification: Method of Use
Expires: 2032-04-30
Drug substance claim: No
Drug product claim: No
Assignee: Veroscience LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.